vertigo
VERTIGO

Vertigo is having a sensation of spinning of either the surrounding or within oneself but physical movement does not exist.

It may be secondary to different causes that may be determined by numerous factors eg timing and duration, aggravating conditions or associated symptoms.
Central vertigo originates from the central nervous system (brainstem or cerebellum). It is uncommon but more serious and should be ruled out immediately.
Peripheral vertigo originates from the labyrinth or vestibular nerve.

Vertigo Management

Follow Up

Benign Paroxysmal Positional Vertigo

  • Within 1 month after an initial period of observation or treatment, the patient is evaluated for symptom resolution or treatment failure due to persistence of benign paroxysmal vertigo or there is a presence of underlying peripheral vestibular or central nervous system disorders to confirm symptom resolution
  • The patient should be counseled at the start of treatment regarding the importance of follow-up
Editor's Recommendations
Most Read Articles
2 days ago
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Pearl Toh, 22 Oct 2020
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Jairia Dela Cruz, Yesterday
The selective serotonin reuptake inhibitor escitalopram holds promise in the prevention of Alzheimer’s disease, reducing amyloid-β-42 levels in cerebrospinal fluid and brain tissue in older adults with normal cognitive function, according to recent evidence.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.